PMID- 24706266
OWN - NLM
STAT- MEDLINE
DCOM- 20150306
LR  - 20230813
IS  - 1558-9307 (Electronic)
IS  - 0024-4201 (Linking)
VI  - 49
IP  - 7
DP  - 2014 Jul
TI  - Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while 
      increasing HDL levels in serum from patients with type-2 diabetes.
PG  - 695-701
LID - 10.1007/s11745-014-3901-z [doi]
AB  - To our knowledge, no reports are available indicating the favorable effects of 
      synbiotic bread consumption on blood lipid profiles among patients with type 2 
      diabetes mellitus (T2DM). This study was conducted to evaluate the effects of the 
      daily consumption of synbiotic bread on blood lipid profiles of patients with 
      T2DM. This randomized double-blinded controlled clinical trial was performed with 
      78 diabetic patients, aged 35-70 years. After a 2-week run-in period, subjects 
      were randomly assigned to consume either synbiotic (n = 26), probiotic (n = 26) 
      or control bread (n = 26) for 8 weeks. The synbiotic bread contained viable and 
      heat-resistant probiotic Lactobacillus sporogenes (1 x 10(8) CFU) and 0.07 g 
      inulin (HPX) as prebiotic per 1 g. The probiotic bread contained L. sporogenes (1 
      x 10(8) CFU) per 1 g. Patients were asked to consume the synbiotic, probiotic and 
      control breads three times a day in a 40 g package for a total of 120 g/day. 
      Biochemical measurements including blood lipid profiles were conducted before and 
      after 8 weeks of intervention. Consumption of the synbiotic bread, compared to 
      the probiotic and control breads, led to a significant decrease in serum TAG (P = 
      0.005), VLDL-C (P = 0.005), TC/HDL-C (P = 0.002) and a significant increase in 
      serum HDL-C levels (P = 0.01). No significant effect of synbiotic bread 
      consumption on FPG, TC, LDL-C and non-HDL-C levels was seen compared to the 
      probiotic and control breads (P > 0.05). Trial registry code: http://www.irct.ir 
      IRCT201311215623N13.
FAU - Shakeri, Hossein
AU  - Shakeri H
AD  - Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan 
      University of Medical Sciences, Kashan, Islamic Republic of Iran.
FAU - Hadaegh, Haleh
AU  - Hadaegh H
FAU - Abedi, Fatemeh
AU  - Abedi F
FAU - Tajabadi-Ebrahimi, Maryam
AU  - Tajabadi-Ebrahimi M
FAU - Mazroii, Navid
AU  - Mazroii N
FAU - Ghandi, Yaser
AU  - Ghandi Y
FAU - Asemi, Zatollah
AU  - Asemi Z
LA  - eng
SI  - IRCT/IRCT201311215623N13
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140406
PL  - United States
TA  - Lipids
JT  - Lipids
JID - 0060450
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Lipoproteins, VLDL)
RN  - 0 (Triglycerides)
SB  - IM
EIN - Lipids. 2023 Sep;58(5):253. PMID: 37574208
MH  - *Bread
MH  - Diabetes Mellitus, Type 2/*blood
MH  - *Diet
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Lipoproteins, HDL/*blood
MH  - Lipoproteins, VLDL/*blood
MH  - Male
MH  - Middle Aged
MH  - *Synbiotics
MH  - Triglycerides/*blood
EDAT- 2014/04/08 06:00
MHDA- 2015/03/07 06:00
CRDT- 2014/04/08 06:00
PHST- 2014/02/11 00:00 [received]
PHST- 2014/03/20 00:00 [accepted]
PHST- 2014/04/08 06:00 [entrez]
PHST- 2014/04/08 06:00 [pubmed]
PHST- 2015/03/07 06:00 [medline]
AID - 10.1007/s11745-014-3901-z [doi]
PST - ppublish
SO  - Lipids. 2014 Jul;49(7):695-701. doi: 10.1007/s11745-014-3901-z. Epub 2014 Apr 6.